39results about How to "Realize non-invasive testing" patented technology

The invention discloses a detection method and an application of lung cancer genes. According to the application, the detection method comprises the following steps: constructing a cfDNA library, and conducting hybrid capturing on the cfDNA library by virtue of 12659 probes which are designed in accordance with 105 lung cancer associated genes, sequencing the genes by virtue of a computer, and conducting data analysis on a sequencing result, so that comprehensive and accurate lung cancer gene information is obtained. According to the application, the detection method can implement with a small amount of peripheral blood, so that noninvasive detection is actually achieved. The detection method disclosed by the invention, by capturing, sequencing and analyzing important lung cancer genes in ctDNA, can be used for screening lung cancer in the early stage; therefore, related medication gene mutation information is provided for patients with the lung cancer, and an important reference is provided for the early diagnosis of the lung cancer, personalized accurate medication guidance, effectiveness evaluation and prognosis dynamic monitoring.

The invention provides a method for building an ALK gene fusion mutation detection library. The method includes the steps of firstly, extracting DNA, and fragmenting the DNA; secondly, building a DNA pre-library; thirdly, cyclizing the DNA; using ALK specific primers to perform PCR amplification, and enriching a target area to generate the final library. The invention further provides a kit for building the ALK gene fusion mutation detection library and a method for detecting ALK gene fusion mutation. The method for building the ALK gene fusion mutation detection library has the advantages that the method targeted at ALK recombination hot spot regions is excellent in sensitivity when being combined with the second-generation high-through sequencing technology, and plasma DNA or tissue DNA can be used as the initial material to accurately detect the information of ALK gene fusion mutation; in addition, when the plasma DNA is used as the initial material, noninvasive detection of ALK gene fusion mutation and crizotinib drug-resistant mutation is achieved.

The invention provides a skin image information processing-based age testing method. According to the invention, based on the mining of age-related changing texture information of skin surface, a novel, simple and noninvasive age estimation method is provided for medical workers. According to the skin image information processing-based age testing method, a skin image of the middle segment of the ventral side of a forearm is acquired in a noninvasive manner; preprocessing and feature extraction are performed on the acquired skin image, so that relevant parameters of skin grooves and skin ridges are obtained; and the correlation between the parameters and the age is analyzed by using a statistical method, so that the mathematical model of age inference can be obtained. As indicated by statistical results, the skin texture parameters obtained through adopting the method all have high linear correlation with the edge; and when the edge inference model which is obtained through statistical analysis is tested, high accuracy can be obtained. Thus, the effectiveness of the method in age inference can be proved, and cost required by the method is low, and therefore, the method can be prospectively used for objective inference of medical age.

The present invention provides a multi-gene detection primer probe set for early diagnosis, screening or detection of digestive tract tumors, and belongs to the field of biomedicine. The primer probeset comprises at least two groups selected from the following five groups of primers and probes: (1) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated SDC2 gene; (2) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated SFRRP2 gene; (3) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated SEP9 gene; (4) a forwardprimer, a reverse primer, a Blocker primer and a probe of a methylated CADM1 gene; and (5) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated PAX1 gene. The multi-gene detection primer probe set simultaneously detects two or more methylated markers, is high in sensitivity, good in specificity, convenient in detection, and low in cost, and can be used for early screening and auxiliary diagnosis of the digestive tract tumors.

The invention discloses a system and method for retrieving the corresponding positional relationship of blood vessels under multi-angle arteriography. The system comprises an angiographic machine, an angiographic image receiving module, a center point calibration module, a corresponding feature point detection module and a feature point corresponding blood vessel module; the angiographic machine is used for imaging and collecting a plurality of angiographic images of a projection position; the angiographic image receiving module is used for receiving the images and transmitting the images to the center point calibration module; the center point calibration module is used for calibrating the center point deviation caused by a multi-angle arteriography system, and a result is transmitted to the feature point detection module; the feature point detection module receives a plurality of feature points of a reference projection angle angiographic image target blood vessel, and corresponding feature points of a second projection angle image is detected through a spatial polar line constraint relationship; the feature point corresponding blood vessel module is used for determining the blood vessels where the feature points are located. By means of the system and method, the complexity of existing corresponding relationship detection is simplified, and the accuracy of the result is ensured while noninvasive detection is achieved.

The invention provides a method for carrying out in vitro diagnosis on concentration of helicobacter pylori in a stomach by taking a wavelength scanning-cavity ring down spectroscopy (WS-CRDS) as a detection technology and taking urea marked by carbon-13 isotope as a tracer agent through detecting carbon-13 abundance change of carbon dioxide in breathing air of a patient. A measurement technology comprises the following steps: leading generated laser into a light reflection unit to be circulated and reflected until small amount of laser strength leaked by the light reflection unit reaches a threshold value; stopping inputting the laser until light cavity attenuation is zero; inputting CO2-containing gas exhaled by the patient into a resonance cavity unit to accelerate oscillation of laser; detecting a light intensity resonance difference in a resonance cavity by using the laser with adjustable wavelength; calculating a time difference of inputting target gas CO2 and hollow cavity oscillation to form a characteristic spectrum line; integrating characteristic spectrum peaks of 13CO2 and 12CO2; and measuring carbon-13 abundance of the target gas CO2; and comparing delta13CO2 of the carbon-13 abundance in the CO2 before and after taking the urea marked by the carbon-13 isotope as the tracer agent, wherein a high-confidence coefficient clinical statistical result shows that a direct ratio is formed by the delta13CO2 and Hp content. The method is accurate, flexible, environmentally friendly and economical, and is suitable for clinical large-scale application.

The invention relates to a prostate cancer early diagnosis or prognosis evaluation marker lncRNA malat1 and application thereof. The marker is an exosome-derived long-chain non-coding RNA (lncRNA) malat1, has a good indicating effect on the early diagnosis of a prostate cancer, can realize the non-invasive detection on the prostate cancer and has higher sensitivity and specificity when being compared with a conventional prostate cancer non-invasive detection method, thereby clinically avoiding the unnecessary puncture biopsy for prostate cancer suspected patients. In addition, the marker alsohas a good prediction effect on the prognosis of the prostate cancer and favorably guides the recurrence monitoring and the early clinical intervention of the patients.

The invention discloses a noninvasive blood sugar detection device based on a raman scattering spectrum. The noninvasive blood sugar detection device based on a raman scattering spectrum comprises a semiconductor laser, an optical fiber beam splitter, an optical fiber probe, a light filter, a raman spectrometer, a first circuit switch, a second circuit switch, a phase locking amplifier, a heart rate measuring apparatus and a computer. According to the noninvasive blood sugar detection device based on a raman scattering spectrum disclosed by the invention, raman scattering light contains rich molecular vibration information, the characteristics that the raman scattering spectrum having different molecules has different features are utilized, the raman scattering spectrum is used for recognizing molecules; and through the relative value of a glucose characteristic peak at the position of 1125cm-1 in the raman scattering spectrum in pure blood to the hemoglobin characteristic peak value at the position of 1549cm-1, and real-time human body blood sugar concentration data measured by a blood sugar biochemistry instrument, a standard straight line L of the relationship between the relative peak value of the glucose characteristic peak at the position of 1125cm-1 and the human body blood sugar concentration is constructed, and finally noninvasive real-time detection of the human bodyblood sugar is realized. The noninvasive blood sugar detection device disclosed by the invention has the advantages of being high in precision, pollution-free, harmless to human bodies and the like, and has great application prospects in the field of biological noninvasive detection.

The invention discloses a kit for early screening of the lung cancer based on peripheral blood. The kit comprises a connector, a PCR primer and a capture probe. The connector comprises a Tag sequence,a Poly N sequence, a first hairpin sequence, a second hairpin sequence, a first index sequence, a first common primer combination sequence, a second common primer combination sequence and dUTP, and the first index sequence is used for distinguishing different peripheral blood samples; the PCR primer is a primer designed for 358 genes which are related to the pulmonary nodule and indirectly influence proliferation and differentiation of cells, and the PCR primer is used for being combined with the connector; the capture probe is a probe designed for the 358 genes which are related to the pulmonary nodule and indirectly influence proliferation and differentiation of the cells, and the capture probe is used for capturing a cfDNA area of plasma in the peripheral blood samples. The provided kit can be applied to early disease screening of the lung cancer, and the pulmonary nodule is diagnosed in a noninvasive and high-sensitivity mode.

The invention discloses a deafness gene detection kit. The deafness gene detection kit is suitable for detection of a GJB3 gene locus, a GJB2 gene locus, a mitochondrial DNA locus and a SLC26A4 gene locus. The detection kit comprises primers of GF1 to GF9 and GR1 to GR9. The probes comprise sequence probes P1 to P18. Each sequence probe comprises a wild-type probe and a mutant probe. The deafnessgene detection kit realizes non-invasive prenatal detection for pregnant women and early finds deaf children.

The invention discloses a kit for detecting benign or malignant pulmonary nodules and an application thereof. The kit comprises the following components: (A) a detection reagent, wherein the detection reagent is magnetic beads treated by streptavidin; (B) a first-type detection component which is an independently designed adapter, wherein the sequence of partial nucleotide is shown in SEQ ID NO:1; (C) a second-type detection component, wherein the detection component is a primer designed according to 358 genes related to the pulmonary nodules, and the sequence of partial primers is shown in SEQ ID NO:2 and SEQ ID NO:3; and (D) a third-type detection component, wherein the third-type detection component is 75642 capture probes designed according to 358 genes related to the pulmonary nodules, and the sequence of partial probes is shown in SEQ ID NO:4 and SEQ ID NO:5. The kit can be used for screening early diseases of lung cancer and discriminating the benign and malignant pulmonary nodules.

The invention provides a bladder cancer detection kit and application thereof. By detecting expression of at least one of miR-423-5p, miR-203-3p, miR-21-5p and miR-30b-5p in exosomes from tumors, thekit and system can be used for detecting tumors by utilizing urine which is a biological sample and are high in stability and accurate in quantification. The kit is rapid, low in cost, high in accuracy and high in sensitivity.

The invention discloses an ultrasonic cross-scale and multi-parameter detection imaging platform and method, and belongs to the technical field of ultrasonic imaging. Comprising the following steps: acquiring channel data, ultrasonic image data and video data which are not subjected to beam forming; performing beam forming on the channel data to obtain radio frequency data; realizing passive acoustic imaging by using channel data according to frame number selection; using radio frequency data to obtain cross-scale ultrasonic structure images: super-resolution imaging, multi-mechanical parameter imaging and microbubble subharmonic blood pressure imaging; obtaining the ultrasonic three-dimensional image by processing an ultrasonic image, video data, passive acoustic imaging and a cross-scale ultrasonic structure image based on a three-dimensional reconstruction and visualization technology. The platform comprises an ultrasonic signal acquisition control sub-platform, a cross-scale multimode imaging sub-platform and a three-dimensional reconstruction sub-platform. According to the invention, multi-mode imaging based on ultrasonic cross-scale and multi-parameter detection is realized.

The invention provides a detection method of a guide wire-free FFR, a guide wire-free IMR and a guide wire-free CFR. The method comprises the following steps: acquiring a 2D coronary image of a blood vessel to be measured; constructing a 3D blood vessel model according to the 2D coronary artery image; acquiring the central arterial pressure of the blood vessel to be measured by using a non-invasive measurement method; constructing a 3D coronary CFD model of the blood vessel to be measured at least according to the 3D blood vessel model and the central arterial pressure; and calculating a guidewire-free CFR, a guidewire-free FFR and a guidewire-free IMR according to the 3D coronary CFD model. The non-invasive detection of CFR, FFR and IMR by adopting a DSA image auxiliary technology is realized.

The invention provides a device for noninvasively detecting indocyanine green content in bodies. The device includes a laser emitting device that can emit single wavelength or multi-wavelength with the wavelength of 805 nm, and photoacoustic signal detection and conversion devices; and preferably, the device also includes an ultrasonic positioning device, and the ultrasonic positioning device canaccurately detect the indocyanine green content in a blood vessel at a specific position without being disturbed by other tissue. Through the device, the noninvasive detection on the indocyanine greencontent in blood can be realized; rapid assessment on hepatic functional reserve can be realized; and therefore, the device has good commercial prospects.

The invention provides a noninvasive blood glucose screening system based on a gas discharge imaging technology. The system comprises a GDV instrument, a meridian energy parameter acquisition module, a disease parameter and meridian energy parameter correlation analysis module, a mathematical model establishment module and a diabetes attack score determination module. The system is used for screening out meridian energy parameters related to diabetes diagnosis according to a fingertip glow image of a user, establishing a mathematical model according to the meridian energy parameters, and obtaining a diabetes attack score cut-point according to the meridian energy parameters related to diabetes diagnosis and the mathematical model, so as to determine the risk degree of the user suffering from diabetes according to the diabetes attack score cut-point. According to the noninvasive blood glucose screening system based on the gas discharge imaging technology, the diabetes attack risk value and corresponding conditioning suggestions can be obtained by collecting two photos of fingers of the left hand and the right hand of the user, the coverage rate of diabetes screening can be increased, and part of hidden or early diabetes patients can be found in time.

The present application discloses a prognostic biomarker and a detection kit for patients with intrahepatic cholangiocarcinoma. Using the set of polynucleotide sequences shown in SEQ ID NO.1‑SEQ ID NO.24 as biomarkers, methylation analysis was performed on these promoter regions, and an effective methylation scoring model was constructed to realize liver Accurate assessment of prognostic survival in patients with internal cholangiocarcinoma. This biomarker can be used as a single predictor of prognosis in patients with intrahepatic cholangiocarcinoma or as a predictor of survival in patients with intrahepatic cholangiocarcinoma based on multiple variables including gene promoter methylation scores.

One or more embodiments of the invention provide a blood glucose monitoring device, which is characterized by comprising a device main body, a parameter detection system and a blood glucose calculation system are arranged in the device main body, wherein the parameter detection system detects various physical sign parameters of a detected person and sends the parameters to the blood glucose calculation system, and the blood glucose calculation system calculates a blood glucose concentration value according to the parameters sent by the parameter detection system. The noninvasive detection can be achieved, convenience and rapidness are achieved, and pain of a detected person is relieved.

The invention discloses application of an ST3GAL6-AS1 gene as well as a specific primer pair and a kit, and the specific primer pair aiming at the ST3GAL6-AS1 gene comprises an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is as shown in SEQ ID No. 1; and the nucleotide sequence of the downstream primer is as shown in SEQ ID No.2. The kit comprises a specific primer pair aiming at the ST3GAL6-AS1 gene. The ST3GAL6-AS1 gene is used as a detection marker of MM and MRD for the first time and is used for detecting multiple myeloma and multiple myeloma residues, high sensitivity and high specificity are achieved, and noninvasive detection can be achieved; and the kit disclosed by the invention not only can be applied to qualitative detection of MM and MRD, but also can be used for quantitatively determining the invasion and migration capabilities of tumor cells in the body of a patient through comparison with a reference gene.

The invention provides a device for detecting the content of indocyanine green in the body, which includes: a single-wavelength or multi-wavelength laser emitting device with a wavelength of 805nm, and a photoacoustic signal detection and conversion device. The present invention preferably also includes an ultrasonic positioning device, which can accurately detect the content of indocyanine green in a blood vessel at a specific location without interference from other tissues. The invention can realize the non-invasive detection of the content of indocyanine green in the blood, realize the rapid evaluation of the liver reserve function, and has good commercialization prospect.

The present invention provides a bladder cancer detection kit and its application, by detecting at least one of miR-423-5p, miR-203-3p, miR-21-5p, and miR-30b-5p in tumor-derived exosomes To provide a kit and system that can detect tumors using urine as a biological sample, with high stability and accurate quantification. It is a fast, low-cost, high-accuracy, and high-sensitivity kit .

The invention relates to a system for measuring the conduction time of pulse waves between cerebral arteries and cerebral veins. The system comprises a signal acquisition device, a signal processing device and a display device, wherein the signal acquisition device is connected with the signal processing device through a communication interface module; and the output end of the signal processing device is connected with the display device. The cerebral blood flow signal acquisition method comprises the following steps: 1) arranging a fixed probe device with two cerebral blood flow signal acquisition devices; 2) synchronously acquiring cerebral blood flow signals; and 3) exchanging the positions of the two cerebral blood flow signal acquisition devices. The medicinal uses of the system are as follows: 1) synchronously acquiring the cerebral blood flow signals of ipsilateral encephalic large arteries (aorta) and encephalic deep veins of a person to be tested at a resting state; and 2) measuring the time difference of the two cerebral blood flow signals. Through the system provided by the invention, noninvasive detection is realized on the conduction time of pulse waves between the cerebral arteries and the cerebral veins; and the clinical practicality is strong, the stiffness of cerebral arteriolae can be accurately and directly reflected, and the risk of apoplexy is estimated, thus being beneficial for early discovering and preventing cerebral arteriosclerosis of patients.

The non -invasive blood glucose detection device based on the Raman scattering spectrometer includes semiconductor lasers, fiber fiber signs, optical fiber probes, filters, Raman spectrometers, first circuit switches, second circuit switchesYimen computer; the present invention uses the rich molecular vibration information contained in Raman's scattered light, and uses different molecular scattering spectra to identify the molecules with the Raman scattered spectrum, through the pure blood, through the pure blood1125cm in Raman scattering spectrum ‑1 Glucose characteristic peak for 1549cm ‑1 The relative values of the peak value of hemoglobin at the point and the real -time human blood glucose concentration data measured by the blood glucose biochemical meter measurement, establish 1125cm ‑1 The relative peak of glucose characteristics peaks and human blood glucose concentration standards straight line L, eventually realized non -invasive and real -time testing of human blood sugar; the present invention has the advantages of high accuracy, pollution -free, harmless to the human body, and in the field of biological non -invasive testing.Wide application prospects.

The invention relates to a neck and brain arterial pulse wave speed measurement system, which is characterized by comprising a signal collection device, a signal processing device, a display device and a communication interface module, wherein the signal collection device is connected with the signal processing device through the communication interface module, the output end of the signal processing device is connected with the display device, the signal collection device is used for synchronously sampling blood flow signals at the tail sections of a common carotid artery and an internal carotid artery and converting the blood flow signals to corresponding digital signals, the signal processing device is used for processing synchronously obtained brain blood flow signals to obtain time difference among the signals, and the display device is used for displaying parameters of the blood flow signals and parameters of the time difference among the signals. The neck and brain arterial pulse wave speed measurement system achieves noninvasive detection on neck-brain arterial pulse wave speed, is accurate and reliable in results and strong in clinical practicality, reflects stiffness conditions of the cerebral artery more accurately and directly, estimates apoplexy risks, and is beneficial to early discovery and precaution of apoplexy.

The invention relates to a prostate cancer early diagnosis or prognosis evaluation marker lncRNA malat1 and application thereof. The marker is an exosome-derived long-chain non-coding RNA (lncRNA) malat1, has a good indicating effect on the early diagnosis of a prostate cancer, can realize the non-invasive detection on the prostate cancer and has higher sensitivity and specificity when being compared with a conventional prostate cancer non-invasive detection method, thereby clinically avoiding the unnecessary puncture biopsy for prostate cancer suspected patients. In addition, the marker alsohas a good prediction effect on the prognosis of the prostate cancer and favorably guides the recurrence monitoring and the early clinical intervention of the patients.

The invention discloses a screening method of tumor markers or a combination thereof. The screening method meets the following conditions: 1) screening tumor-related markers by using one or more indexes including a single base substitution feature; and / or 2) comprising a step of detecting a single base substitution feature. The invention also provides a tumor risk prediction, screening and / or diagnosis model construction method based on the screening method, a cancer risk prediction, screening and / or diagnosis method, and a related tumor marker combination, a kit, a system, a device, a computer readable storage medium and equipment.

The invention provides a method for constructing and detecting ALK gene fusion mutation library comprising the following steps: 1) extracting DNA and fragmenting it; 2) constructing a DNA pre-library; 3) circularizing DNA; 4) using ALK specific PCR amplification was performed with specific primers, and the target region was enriched to generate the final library. The invention also provides a kit for constructing a library for detecting ALK gene fusion mutations and a method for detecting ALK gene fusion mutations. The library construction method targeted at ALK recombination hotspots provided by the present invention combined with the second-generation high-throughput sequencing technology has excellent sensitivity, and can accurately detect information on ALK gene fusion mutations using plasma DNA or tissue DNA as starting materials. In addition, when plasma DNA is used as the starting material, the present invention also realizes the non-invasive detection of ALK gene fusion mutation and crizotinib resistance mutation.

The invention provides a blood glucose detecting method based on a near-infrared technology. The method comprises the steps of conducting near-infrared light radiation on an object to be detected and measuring a blood-flow volume change at the same time to obtain near-infrared spectroscopic data and blood-flow volume pulse wave data as detecting data; predicting the detecting data according to a preestablished blood glucose detecting model to obtain a blood glucose detecting result. Besides, the invention further provides a blood glucose detecting system based on the near-infrared technology and an electronic device. According to the blood glucose detecting device and method based on the near-infrared technology and the electronic device, non-invasive detection of blood glucose can be achieved, the operation is convenient, and the safety is high.